Bile duct cancer, or BTC, is a tough and aggressive disease that comes in three main types: intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC). It's not common worldwide, but it's a big deal in some places.

        Korea, for instance, has the second-highest rate of BTC in the world and the highest death rate. This makes it crucial to dig deeper into why this cancer is so prevalent there.

        One big reason is the liver fluke infection, which is more common in Korea than in many other countries. This parasite can cause long-term inflammation and damage to the bile ducts, leading to cancer.

        Another factor is the hepatitis B virus (HBV), which is also more common in Korea. This virus can cause liver damage and increase the risk of BTC.

        But it's not just about these infections. The genetic makeup of BTC in Korean patients is different from what's seen in other parts of the world. For example, Korean patients with ICC have lower rates of IDH1 mutations and FGFR2 fusions. On the other hand, GBC patients in Korea have a higher rate of ERBB2 amplification.

        These genetic differences matter because they can affect how the cancer responds to treatment. In Korea, two drugs, ivosidenib and pemigatinib, have been approved for BTC patients with specific genetic mutations.

        Understanding these unique features of BTC in Korea can help guide future research and improve treatment options. By comparing Korean data with global data, researchers can gain insights into the disease's behavior and develop more effective therapies.

        It's also important to note that BTC is not just a Korean problem. It affects people worldwide, and understanding its unique features in different regions can help in the global fight against this disease.

Bile Duct Cancer: Why Korea Stands Out

Actions